✉news ScienceBiology first seen 7 d ago, last 6 d ago, peak #37
Whole Genome Oncodetect MRD Test Now Available for Solid Tumors
Original: Whole Genome Oncodetect MRD Test Is Now Available for Solid Tumors
A whole genome-based minimal residual disease (MRD) test, Oncodetect, is now available for patients with solid tumors. The test is designed to detect traces of cancer DNA after treatment, helping clinicians monitor for recurrence earlier than conventional imaging allows. Clinicians and industry observers note it could expand access to genomic MRD monitoring, which has so far been limited mainly to blood cancers and select tumor types.
Why now: The launch gives oncologists a new genomic tool for detecting cancer recurrence early in solid tumors, a fast-moving area of cancer care.
Rank over time, top of the chart is #1. 10 snapshots from 6 d ago to 6 d ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/3771358